Home > Insider Trading > Filing (0001628280-24-040284)

Filing Details

Accession Number:: 0001628280-24-040284
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-09-12 20:03:02
Reporting Period:: 2024-09-10

Accepted Time:: 2024-09-12 20:03:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1588978	Procept Biorobotics Corp	PRCT	Surgical & Medical Instruments & Apparatus (3841)	260199180

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1881616	Rohit Antal Desai	C/O Procept Biorobotics Corporation 150 Baytech Drive San Jose CA 95134		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-09-10	18,690	$75.78	298,828	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-09-10	17,810	$76.60	281,018	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-09-11	8,904	$75.90	272,114	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-09-11	4,880	$77.09	267,234	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-09-11	20,732	$78.12	246,502	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-09-11	4,182	$78.67	242,320	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-09-12	4,458	$78.00	237,862	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-09-12	2,318	$78.89	235,544	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-09-12	9,402	$79.78	226,142	No	4	S	Indirect	By The 2:22 DNA Trust
Common Stock	Disposition	2024-09-12	28,689	$80.65	197,453	No	4	S	Indirect	By The 2:22 DNA Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust
No	4	S	Indirect	By The 2:22 DNA Trust

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.24 to $76.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.24 to $76.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.435 to $76.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.46 to $77.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.48 to $78.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.48 to $79.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.27 to $78.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.33 to $79.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.33 to $80.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.33 to $81.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.